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Joinville stroke biobank: study protocol and 
first year’s results
Biobanco de acidente cerebrovascular de Joinville: protocolo de estudos e resultados dos 
primeiros anos
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According to the Global Burden of Disease Study, in 
2013, there were almost 25.7 million stroke survivors (71% 
with ischemic stroke (IS)), 6.5 million deaths from stroke 
(51% died from IS), 113 million disability-adjusted life years 
due to stroke (58% due to IS) and 10.3 million new strokes 
(67% IS) worldwide1. The INTERSTROKE study defined the 
1Universidade da Região de Joinville, Joinville SC, Brasil;
2Universidade Federal do Ceará, Sobral CE, Brasil;
3Universidade de São Paulo, Ribeirão Preto SP, Brasil;
4Universidade Federal do Mato Grosso do Sul, Campo Grande MS, Brasil;
5Universidade Federal do Rio Grande do Sul, Porto Alegre RS, Brasil;
6Universidade de Campinas, Campinas SP, Brasil;
7Instituto Brasileiro de Neurociência e Neurotecnologia, Campinas SP, Brasil.
Correspondence: Leslie Ecker Ferreira; Rua Paulo Malschitzki, 10; 89219-710 Joinville SC; E-mail: leslie.ferreira@univille.br
Conflict of interest: There is no conflict of interest to declare.
Support: CNPq - (Grant Number: 402396-2013/08) and Coordination for the Improvement of Higher Education Personnel (CAPES) (PROCAD 183768).
Received 20 May 2017; Received in final form 15 July 2017; Accepted 08 August 2017.
ABSTRACT
Aiming to contribute to studies that use detailed clinical and genomic information of biobanks, we present the initial results of the first 
Latin American Stroke Biobank. Methods: Blood samples were collected from patients included in the Joinville Stroke Registry and four 
Brazilian cities. Demographic socio-economic data, cardiovascular risk factors, Causative Classification System for Ischemic Stroke, Trial of 
Org 10172 in Acute Stroke Treatment and National Institutes of Health scores, functional stroke status (modified Rankin) and brain images 
were recorded. Additionally, controls from both geographic regions were recruited. High-molecular-weight genomic DNA was obtained from 
all participants. Results: A total of 2,688 patients and 3,282 controls were included. Among the patients, 76% had ischemic stroke, 12% 
transient ischemic attacks, 9% hemorrhagic stroke and 3% subarachnoid hemorrhage. Patients with undetermined ischemic stroke were 
most common according the Trial of Org 10172 in Acute Stroke Treatment (40%) and Causative Classification System for Ischemic Stroke 
(47%) criteria. A quarter of the patients were under 55 years of age at the first-ever episode. Conclusions: We established the Joinville 
Stroke Biobank and discuss its potential for contributing to the understanding of the risk factors leading to stroke.
Keywords: stroke; genetics, biobank.
RESUMO
Com o objetivo de contribuir para estudos que utilizam informações clínicas e genômicas de biobancos, apresentamos os resultados 
iniciais do primeiro Biobanco Latinoamericano em Acidente Vascular Cerebral (AVC). Métodos: Foram coletadas amostras de sangue 
de pacientes recrutados pelo Registro de AVC de Joinville e posteriormente de quatro cidades brasileiras. Foram registrados dados 
socioeconômicos demográficos, fatores de risco cardiovasculares, Causative Classification System (CCS), Trial of Org 10172 in Acute Stroke 
Treatment, National Institutes of Health, estado funcional (Rankin modificado) e imagens cerebrais. Adicionalmente, foram recrutados 
controles das regiões geográficas correspondentes. Obteve-se DNA genômico de todos participantes. Resultados: Foram incluídos 2688 
pacientes e 3282 controles. Entre os pacientes, 76% tiveram AVC isquêmico, 12% ataques isquêmicos transitórios, 9% AVC hemorrágico 
e 3% hemorragia subaracnóidea. Os casos indeterminados foram os mais frequentes e classificados de acordo com TOAST (40%) e CCS 
(47%). Um quarto dos pacientes tinham menos de 55 anos no primeiro evento. Conclusões: Estabelecemos o Joinville Stroke Biobank, 
e discutimos aqui seu potencial na compreensão dos fatores de risco do AVC.
Palavras-chave: acidente vascular cerebral; genética; biobancos.
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population-attributable risks for ischemic and hemorrhagic 
strokes in 22 countries, concluding that 10 classical cardio-
vascular risk factors are associated with 90% of the risk of 
stroke2. However, twins and familial aggregation studies sug-
gest that the risk of stroke has a substantial genetic compo-
nent3. Although genetics, and more recently genomics, play 
an increasingly large role in the practice of medicine, the 
daily clinical care of patients suffering from stroke has not 
significantly been affected by the advances in these fields. 
Therefore, one can assume that there is still much knowledge 
about stroke genetics and genomics needing to be translated 
into clinical practice.
Currently, there are tremendous efforts to understand the 
genetic basis of both rare and common cardiovascular and 
stroke disorders through strategies such as genome-wide 
association studies and next-generation sequencing studies4. 
In this scenario, it has been pointed out that well-established 
stroke biobanks with close collaboration between clinicians 
and geneticists are essential for supplying the biological and 
clinical information required for these large-scale studies4,5,6. 
To address these challenges specifically, recent coopera-
tive efforts have been launched such as the Stroke Genetics 
Network and Bio-Repository of DNA in Stroke7,8.
As defined by Brazilian regulatory guidelines, a biobank 
represents an organized collection of human biological mate-
rial and associated data that are prospectively collected and 
stored for research purposes, in accordance with predefined 
technical, ethical and operational standards, under institu-
tional responsibility and management. We present the study 
protocol and current status of the Joinville Stroke Biobank 
( JSB), the first Latin American DNA biobank of stroke.
METHODS
Participants and samples
The current biobank originated from two sequential ini-
tiatives to study epidemiological aspects of stroke in recent 
years in Brazil9. The phenotypic data were extracted from the 
Joinville Stroke Registry, which is a population-based regis-
try that has been ongoing since 2005. In 2013, the registry 
became supported by a municipal law10. The beginning of case 
and control data ascertainment, blood extraction and DNA 
storage took place in 2010. These samples and data, which 
are still being collected and processed in Joinville, constitute 
phase I of the JSB, which has no deadline for completion. 
Phase II was launched in 2015, when the JSB started to 
receive blood samples and phenotypic data from four other 
Brazilian cities. This constitutes a task force of the Brazilian 
Consortium of Stroke Research, which is sponsored by 
the Brazilian Ministry of Health and the National Council 
for Scientific and Technological Development, to define 
stroke incidence trends, case-fatality proportions and the 
prevalence of classic cardiovascular risk factors according 
to the WHO Steps criteria11 in different geopolitical scenar-
ios than Joinville, which has a higher Human Development 
Index than other cities. Data and samples will be collected 
until 2017. 
Central site and contributing sites 
In JSB phase I, inpatients from five hospitals and out-
patient data (mild strokes) from the town of Joinville 
(515,288 inhabitants, 2010 census) were included, whereas 
JSB phase II covered the following cities: Sobral, north-
east region (three hospitals; 147,135 inhabitants), Campo 
Grande, central region (eight hospitals; 774,202 inhabit-
ants), Sertãozinho, south-east region (two hospitals; 101,784 
inhabitants) and Canoas, south region (three hospitals; 
323,827 inhabitants), whose geographic locations are shown 
in the Figure. The central site, as defined by the International 
Stroke Genetics Consortium is located in the facilities at the 
University of the Region of Joinville.
Inclusion and exclusion criteria
Since the beginning of both phases, data and blood 
samples have been collected from each case and related 
controls. Patients included transient ischemic attacks, 
subarachnoid hemorrhages, ischemic strokes and hemor-
rhagic strokes. We included first-ever or recurrent patients, 
regardless of age and sex, residing in one of the five cities. 
All patients had at least one cranial tomography. Stroke 
confirmation and diagnosis were performed as previously 
reported9. In brief, the phenotype of each stroke patient 
Figure. Localization of cities, according to Brazilian 
mesoregions, corresponding to central and contributing sites 
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includes demographic information, social class (according 
to the Brazilian Criteria of Economic Classification based 
on the National Household Sample Survey)12, years of edu-
cation, type of work (manual or not), family history of 
stroke, cardiovascular risk factors, biochemical tests and 
functional status (modified Rankin scale)13. Furthermore, 
IS subtypes were classified according to the modified 
Trial of Org 10172 in Acute Stroke Treatment (TOAST) 
criteria and Causative Classification System for Ischemic 
Stroke (CCS) criteria14,15. Patients with IS of undeter-
mined cause due to negative investigation or cryptogenic 
stroke were classified according to the Embolic Strokes of 
Undetermined Source international work group16. A neu-
roradiologist classified all hemorrhagic strokes as lobar 
and non-lobar subtypes.
Controls were matched by age and gender to patients, 
and individuals with a previous history of stroke or blood 
ties to patients were excluded. In cases of a positive fam-
ily history of stroke, blood samples of all related patients 
and non-stroke relatives were searched for and nominated 
as nuclear cases. 
Phenotyping methods
Table 1 shows the diagnostic examination and the cat-
egories of data retrieved by questionnaires. After 2012, 
the CCS criteria for phenotyping IS patients were also 
employed. The neurologists of all cities in the contributing 
sites were trained by stroke neurologists from the Joinville 
Stroke Registry using the platform available on the CCS 
website15. After the TOAST diagnosis, the clinical history, 
physical examination findings and the results of diagnos-
tic work-up were reviewed for determining the CCS classi-
fication. Ischemic stroke patients with incomplete diagnos-
tic examination were classified as a possible IS subtype or 
received an IS diagnosis as undetermined with incomplete 
evaluation. All Joinville IS diagnoses were blinded for adju-
dication by two authors (FIR and NLC).
Data and blood sample collection 
Patient selection and blood collection were performed 
by neurologists and nurses, respectively. Research nurses 
invited the controls to enroll from among the accompany-
ing persons willing to participate who fulfilled the inclu-
sion criteria. After clarifying the aims of the JSB and the 
corresponding roles of all parties involved, blood sam-
pling (phase I: 12 mL by venous puncture employing com-
mon EDTA-containing vacuum tubes; phase II: finger 
puncture followed by drying and storage on an FTA Elute 
Card®, Whatman, Kent, United Kingdom) of patients and 
controls was performed by research nurses. Baseline data 
included self-declared skin color, collected in strict accor-
dance with the mandatory procedures established by the 
Brazilian Institute of Geography and Statistics for purposes 
of population census. Demographics, socio-economic data, 
cardiovascular risk factors, National Institutes of Health 
Stroke Scale (clinical stroke severity) and functional out-
come can be extracted from the Joinville Stroke Registry, 
which also includes causes and dates of death. The follow-
up of patients is being carried out by phone calls by previ-
ously-trained research nurses in one, three, six, nine and 12 
months in the first year and once a year for the following 
four years after stroke diagnosis. Patients are asked about 
regular visits to a general physician, blood pressure control, 
results of glycated hemoglobin and cholesterol levels, and 
smoking habits. 
An identification code, which comprises numbers that 
denote the date of recruitment, contributing site and entry 
order, was assigned to each patient enrolled. Controls were 
identified using numbers that keep their relationship with 
each matched patient. These identification codes link clini-
cal data and demographics with deposited DNA samples and 
only the biobank managers or authorized personnel have 
access to the key linking samples and phenotypic data.
Processing of samples, DNA extraction and 
quality control
Blood samples from phase I were maintained at 4°C until 
DNA extraction. Whole blood samples were centrifuged for 
10 minutes at 2,500 x g for separation of the buffy coat, which 
contains most of the white blood cells. Thereafter, genomic 
DNA was obtained by the classic “phenol-chloroform” proce-
dure for total DNA extraction. The DNA was resuspended in 
200 µL of buffer TE (10 mM Tris-HCl; 1 mM EDTA; pH 8.0). 
For phase II, we adopted the procedure for large-amount 
DNA extraction, starting with three paper punches of 3 mm 
circles, as recommended by the manufacturer of the FTA 
Elute Card®. The purity and yield of DNA extracted were 
evaluated by spectrophotometry at 260 and 280 nm (Epoch, 
Biotek Instruments, Winooski, USA). Long-term storage was 
considered for A260/A280 ratios in the range 1.8–2.0. Finally, 
DNA was stored in aliquots at -80°C.
Ethical considerations 
The JSB development plan and the informed consent 
forms were both approved by the Institutional Review 
Board of the University of the Region of Joinville and by 
the Brazilian National Commission for Ethics in Research 
(protocol 25000.142907/2013-07), which holds the final 
approval prerogative for biobanks in Brazil. The adopted 
standards and procedures strictly follow the ethical rules 
that came into force in 2011 and are described in Resolution 
441/11 of the National Health Council and in Ordinance 
2.201 of the Brazil Ministry of Health, which correspond to 
the national guidelines for biorepositories and biobanks of 
human biological material for research purposes. The JSB 
also follows the international ethical regulations. All vol-
unteers (patients and controls) are enrolled after written 
informed consent has been given freely by the participants 
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Table 1. Demographic and diagnostic examination data available in the Joinville Stroke Biobank.
Category Description Cases Controls
Sociodemographic
Date of birth/age Y Y
Gender Y Y
Skin color Y Y
City of residence Y Y
Address Y Y
Social status Y N
Education level Y N
Clinical and biochemical data
First-ever event? Y N
Date of enrollment Y N
Hour of enrollment Y N
Creatinine Y N
Triglyceride Y N
Uric acid Y N
Blood glucose Y N
Cholesterol (hdl/ldl) Y N
National Institutes of Health Stroke Scale (admission) Y N
Barthel  Index Y N
Rankin Index Y N
Oxfordshire Community Stroke Project classification (Banford) Y N
TOAST classification Y N
 CCS classification Y N
Premorbid risk factors 
Transient ischemic attack Y Y
Hypertension Y Y
Diabetes mellitus Y Y
Dyslipidemia Y Y
Acute myocardial infarction Y Y
Congestive heart failure Y N
Atrial fibrillation Y N
Smoking Y Y
Alcohol consumption ** Y N
Drug consumption Y N
Physical activity Y N
Diagnostic examination
Brain CT Y N
Brain MRI Y N
Digital angiography Y N
Extracranial vessels evaluation
Ultrasound Doppler Y N
CT – angiography Y N
MR – angiography Y N
Intracranial vessels evaluation
Transcranial Doppler Y N
CT – angiography Y N
MR – angiography Y N
Embolic sources
ECG Y N
Transthoracic echocardiography Y N
Transesophageal echocardiography Y N
24 h Holter Y N
 Outcome measures
Rankin scale (30 days, 6 months, once a year up to 5 years) Y N
Death (cause, date) by death certificate Y N
TOAST: Trial of Org 10172 in Acute Stroke Treatment criteria16; CCS: Causative Classification System criteria17. CT: computed tomography; MRI: magnetic 
resonance imaging. Y: yes (available); N: no (not available). *Self-declared skin color; **current moderate or heavy drinker was defined as 50 g/day, which is 
equivalent to 500 mL or two glasses of wine, 1000 mL of beer or 5 units of spirits, or being intoxicated at least once a week.
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or their legal representatives. The freedom to refuse par-
ticipation or withdraw at any time is guaranteed, and the 
confidentiality of personal data is ensured in all circum-
stances. Free access to information and associated impli-
cations is guaranteed to participants, thereby respecting 
the expression of individual will.
RESULTS
Since 2010, a total of 5,970 DNA samples have been reg-
istered belonging to patients (2,688) and controls (3,282). 
The mean ages of patients and controls were 64.6 ± 19.3 and 
56.9 ± 14.9 years, respectively. Men were more represented 
among the patients (64%; 1,731/2,688), while women were 
more prevalent among controls (68%; 2,226/3,282).
Table 2 shows the distribution of patients and con-
trols per city, as well as their self-declared skin color. White 
individuals predominated in the south (88%) and south-east 
(55%) regions and brown in the north-east (53%) and central 
(41%) regions.
Table 3 shows the distribution of stroke diagnoses of 
patients in the different cities. Most of the patients (76%; 
2,031/2,688) were IS, followed by 12% (319/2,668) transient 
ischemic attacks, 9% (243/2,668) hemorrhagic stroke and 3% 
(95/2,688) subarachnoid hemorrhage. A quarter of all stroke 
patients were aged ≤ 55 years. 
The distribution of IS cases by TOAST criteria (Table 4) was: 
20% (426/2,031) cardioembolic; 22% (440/2,031) small-artery 
occlusion; 16% (317/2,031) large-artery atherosclerosis; 40% 
undetermined (807/2,031) and 2% (41/2,031) other deter-
mined cause. After 2012, patients were also classified by CCS 
criteria (56%; 1,503/2,688). As expected, among IS patients, 
the most common IS subtype was undetermined, not only 
by TOAST criteria (40%; 807/2,031), but also by CCS criteria 
(47%; 718/1,503). Out of those 807 undetermined IS patients 
Table 2.  Baseline characteristics of stroke patients and controls in the Joinville Stroke Biobank database.
City Campo  Grande Canoas Joinville Sertãozinho Sobral All
Demography
Cases (n) 507 187 1619 175 200 2688
Mean age (±SD) (years) 65.2 (14.9) 64.5 (14.3) 64.3 (14.1) 64.9 (15.1) 67.1 (16.1) 64.6 (19.3)
Male [n(%)] 290 (57.2) 100 (53.5) 1185 (73.2) 56 (32) 100 (50) 1731 (64.4)
Skin color [% (n/N)]
White
46.9 49.7 88.2 55.4 29.5 71.2
(238/507) (93/187) (1428/1619) (97/175) (59/200) (1915 /2688)
Black
7.7 16.0 5.4 13.1 16.0 7.8
(39/507) (30/187) (87/1619) (23/175) (32/200) (211/2688)
Brown
41.4 20.9 6.0 29.1 53.5 18.8
(210/507) (39/187) (97/1619) (51/175) (107/200) (504/2688)
Native American
2.0 2.7 0.2 1.1 0.5 0.8
(10/507) (5/187) (4/1619) (2/175) (1/200) (22/2688)
Yellow
1.4 0.5 0.1 1.1 0.5 0.5
(7/507) (1/187) (2/1619) (2/175) (1/200) (13/2688)
Not-declared
0.6 10.2 0.1 0.0 0.0 0.9
(3/507) (19/187) (1/1619) 0.0 0.0 (23/2688)
Controls (n) 180 24 2586) 276 216 3282
Mean age (±SD) years) 50.2 (14.6) 64.56 (13.1) 68.3 (14.7) 50.2 (13,9) 66.3 (15,5) 56.9 (14.9)
Male [n(%)] 61 (33.8) 14 (58.3) 865 (33.5) 65 (23.5) 51 (23.6) 1056 (32.2)
Skin color [% (n/N)]
White
53.9 62.5 90.4 46.7 32.9 80.7
(97/180) (15/24) (2338/2586) (129/276) (71/216) (2650/3282)
Black
0.6 25.0 2.7 6.9 6.5 3.4
(1/180) (6/24) (71/2586) (19/276) (14/216) (111/3282)
Brown
40.0 8.3 6.4 44.2 47.7 14.2
(72/180) (2/24) (166/2586) (122/276) (103/216) (465/3282)
Native American
0.6 4.2 0.0 0.4 0.9 0.2
(1/180) (1/24) (1/2586) (1/276) (2/216) (6/3282)
Yellow
0.6 0.0 0.1 1.4 0.0 0.2
(1/180) 0 (3/2586) (4/276) 0 (8/3282)
Not-declared
4.4 0.0 0.3 0.4 12.0 1.3
(8/180) 0 (7/2586) (1/276) (26/216) (42/3282)
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classified by TOAST criteria, 55% (446/807) were patients 
with an incomplete evaluation, 42% (340/807) were crypto-
genic and 3% (21/807) were undetermined with two or more 
possible causes. Out of those 718 undetermined IS subtypes 
classified by CCS criteria, 25% (370/1,503) were IS patients 
with incomplete evaluation, 17% (262/1,503) were unknown 
other cryptogenic, 8% (61/1,503) were unknown cryptogenic 
embolism and 1% (25/1,503) were unclassified.
DISCUSSION
Up to October 2016, DNA from 5,970 blood samples dis-
tributed among patients (2,688) and controls (3,282) had 
been extracted and stored. Since it is believed that most of 
the genetic variants identified in stroke studies will have 
small, individual effects on disease risk, efforts aimed at the 
successful discovery of the impact of genes have required 
large sample sizes (usually involving tens or hundreds of 
thousands of cases and controls) to achieve sufficient statis-
tical power10. In addition, as with any case-control study, con-
trols should be representative of cases17,18. 
With this in mind, the JSB comprises well-defined 
phenotypes and samples of high-quality DNA. The prior-
ity recruitment of spouses or partners as case-matched 
controls represents a suitable strategy for minimizing dif-
ferences due to environmental effects to which the par-
ticipants (patients and controls) have been exposed. As 
controls are collected in the same geographic region as 
patients, it is reasonable to expect a homogeneous distri-
bution of ethnic backgrounds between patients and con-
trols. On the other hand, despite having inflated influ-
ences due to shared variants and environmental effects 
between patients and controls, the JSB may also provide 
relevant information on familial aggregation analysis. It is 
also noteworthy to clarify that the JSB has a forecast of 
unlimited continuity as, among other factors, the Joinville 
Stroke Registry is supported by a municipal law. This gives 
rise to the fact that if there are cases of stroke in individu-
als previously categorized as a control (since stroke events 
may happen later in life), their biobank status changes, 
but maintains the traceability of the change. This allows 
the possibility of evaluation of the impact on results of 
any studies already performed with the data and samples 
of those individuals who no longer belong to the control 
group. As far as we know, this is the first stroke biobank in 
Latin America, a region with a massive race mixture.
Under TOAST, IS cases are assigned to one of three main 
subtypes (small-artery occlusion, large-artery atherosclero-
sis, cardioembolic); to a rare cause (e.g., carotid or verte-
bral artery dissection); or remain undetermined (because 
of more than one potential cause, incomplete investigation 
or no apparent cause despite complete investigation/cryp-
togenic stroke). The proportion in the undetermined cate-
gory varies, but can be substantial (up to 40% or more), and 
is usually excluded from ischemic subtype-specific analy-
ses19,20. In our cohort, between 22% (TOAST criteria) and 
25% (CCS criteria) were undetermined IS due to incom-
plete investigation. All patients with incomplete investiga-
tion were assigned this diagnosis. In fact, the highly diverse 
sociodemographic scenarios at sites contributing to the JSB, 
including difficulties related to health-care system access 
and imaging diagnostic workup, might have influenced sig-
nificantly. Nevertheless, independent raters may perform 
blinded readjudications of all JSB IS diagnoses whenever 
considered necessary.
Globally, large DNA biobanks have been contributing 
to the understanding of the different genetic architectures 
and pathophysiological aspects of stroke. In this regard, 
the UK Biobank (European and British Asian), Brains-SA 
(India and Sri Lanka), Bio-Repository of DNA in Stroke – 
Middle East (Qatar)21, China Kadoorie Biobank22 and other 
Table 3. Major stroke diagnosis of patients in the Joinville Stroke Biobank database per city [% (n/N)]. 
Variable
City
Campo Grande Canoas Joinville Sertãozinho Sobral All
IS 16.5 (335/2031) 7.5 (152/2031) 60.9 (1238/2031) 5.6 (112/2031) 9.5 (194/2031) 75.5 (2031/2688)
TIA 20.6 (66/319) 1.6 (5/319) 73.1 (233/319) 4.7 (15/319) 0 11.9 (319/2688)
HS lobar - - 11.7 (28/243) 0 - -
HS non-lobar - - 7.8 (19/243) 0 - -
HS non-classified 34.6 (84/243) 11.1 (27/243) 20.1 (49/243) 13.9 (34/243) 0.8 (2/243) 9.1 (243/2688)
SAH 23.1 (22/95) 3.5 (3/95) 54.6 (52/95) 14.6 (14/95) 4.2 (4/95) 3.5 (95/2688)
Young adult   
(≤ 55 years old) 4.3 (118/2688) 0.4 (13/2668) 15.7 (424/2688) 1.9 (52/2688) 1.9 (53/2688) 24.5 (660/2688)
Nuclear cases 0 0 0.4 (7/1619) 0 0 0.4 (7/2688)
All cases 18.9 (507/2688) 6.9 (187/2688) 60.2 (1619/2688) 6.5 (175/2688) 7.5 (200/2688) 2688
IS: ischemic stroke; TIA: transient ischemic attack; HS: hemorrhagic stroke; SAH: subarachnoid hemorrhage.
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collaborative initiatives, such as the International Stroke 
Genetics Consortium, have contributed to the identification 
of several loci associated with IS subtypes. 
Genome-wide association study approaches have been 
adopted for investigating many complex diseases, such as 
stroke, and have been effective in identifying new genetic 
variants associated with the risk of disease. However, for 
stroke studies, genome-wide association studies have so far 
been applied principally in European, North American and 
Japanese populations3,23.
In particular, four loci (PITX2, HDAC9, ZFHX3 and 12q24.2) 
were convincingly implicated by genome-wide association 
studies as associated with IS in European-ancestry patients24,25. 
Recently, a novel locus (rs12122341) was identified at 1p13.2 
(near TSPAN2), associated with large-artery atherosclerosis 
stroke, and the locus 12q24 (near ALDH2) was associated with 
small-artery occlusion26. In addition, the gene TRPV3 was asso-
ciated with cardioembolic stroke after replication of exome 
sequencing analysis, demonstrating that two polymorphisms 
were associated with cardioembolic stroke risk in two cohorts, 




Grande  Canoas  Joinville Sertãozinho Sobral  All
IS subtype by TOAST
Large-artery atherosclerosis 6.9 (22/317) 5.1 (16/317) 81.8 (259/317) 2.8(9/317) 3.4 (11/317) 15.8 (317/2031)
Cardioembolic 12.2 (52/426) 3.2 (14/426) 78.3 (333/426) 2.8(12/426) 3.5 (15/426) 20.2 (426/2031)
Small-artery occlusion 17.1 (75/440) 4.3 (19/440) 6.9 (307/440) 0.9(4/440) 7.9 (35/440) 21.7 (440/2031)
Other determined cause 17.1(7/41) 0 82.9 (34/41) 0 0 2.2(41/2031)
Undetermined 
Cryptogenic/ESUS 5.6 (19/340) 16.2 (55/340) 51.8 (176/340) 2.6 (9/340) 23.8 (81/340) 16.8 (340/2031)
Incomplete investigation 35.6(159/446) 10.8 (48/446) 24.6 (110/446) 17.5 (78/446) 11.4 (51/446) 22.1 (446/2031)
Two or more determined causes 4.7 (1/21) 0 90.6 (19/21) 0 4.7 (1/21) 1.2 (21/2031)
IS subtype by CCS 
Large-artery atherosclerosis
Evident 5.3 (8/150) 10.7 (16/150) 76.7 (115/150) 0 7.3 (11/150) 9.9 (150/1503)
Probable 0 0 92.1(35/38) 7.9(3/38) 0 2.4 (38/1503)
Possible 12(3/25) 0 64 (16/25) 24 (6/25) 0 1.5 (25/1503)
Cardioembolic
Evident 11.7 (18/154) 7.1 (11/154) 75.3 (116/154) 3.2 (5/154) 2.6 (4/154) 10.2 (154/1503)
Probable 0 0 100 (40/40) 0 0 2.5 (40/1503)
Possible 15.7 (8/51) 0 49.1 (25/51) 13.6(7/51) 21.6 (11/51) 3.3 (51/1503)
Small-artery occlusion
Evident 6.8(12/175) 10.3 (18/175) 6.5 (113/175) 5.7(1/175) 17.7 (31/175) 11.5 (175/1503)
Probable 15.1 (10/66) 0 8.2(54/66) 3.1 (2/66) 0 4.3 (66/1503)
Possible 2.1(1/48) 0 87.5 (42/48) 2.1(1/48) 8.3(4/48) 3.1 (48/1503)
Other determined cause
Evident 11.1 (4/36) 0 86.2(31/36) 0 2.7 (1/36) 2.3 (36/1503)
Probable 0 0 100(2/2) 0 0 1.2 (2/1503)
Possible 0 0 0 0 0 0
Undetermined
Unknown cryptogenic embolism 0 0 80.3(49/61) 0 19.7 (12/61) 4.1 (61/1503)
Unknown other cryptogenic 6.1 (16/262) 20.2(53/262) 44.6 (117/262) 26.7(7/262) 26.3 (69/262) 17.4 (262/1503)
Incomplete evaluation 27.6 (102/370) 12.9 (48/370) 24.3 (90/370) 21.3 (79/370) 13.8 (51/370) 24.6 (370/1503)
Unclassified 4(1/25) 24(6/25) 64 (16/25) 4 (1/25) 4 (1/25) 1.7 (25/1503)
Total IS by TOAST (since 2010) 16.5 (335/2031) 7.5 (152/2031)
60.9 
(1238/2031) 5.6 (112/2031) 9.5 (194/2031) 75.5 (2031/2688)
Total IS by CCS (since 2012) 12.2 
(183/1503) 10.1 (152/1503) 57.3 (861/1503) 74.5 (112/1503) 12.9 (195/1503) 72. 0(1503/2100)
IS: ischemic stroke; TOAST: Trial of Org 10172 in Acute Stroke Treatment criteria16; ESUS: Embolic Strokes of Undetermined Source; CCS: Causative Classification 
System criteria17.
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with rs151091899 being the most significant27. Therefore, repli-
cation studies in other populations are determinants in under-
standing the significance of such polymorphisms as stroke risk 
factors. The Brazilian population is one of the most heteroge-
neous populations in the world, comprising an admixture of 
Native Americans, Europeans and Africans28. The admixture 
process occurred through different means in Brazilian geo-
graphic regions. For instance, the Native American contribu-
tion is more pronounced in northern Brazil, the African con-
tribution is more elevated in the north-east, and the south 
features a European predominance with few Native American 
and African influences29. Consequently, the JSB, unlike other 
biobanks8,22,23, comprises an ideal admixed population with 
great ethnic variability linked to epidemiological and clinical 
data, which may allow confirmation of polymorphisms found 
in specific populations, contributing to global understanding 
of genetic mechanisms involved in stroke.
In conclusion, the clinical, environmental and epide-
miological issues related to the different types of stroke, 
combined with the large genetic variability captured by the 
JSB, may increase the chance of identifying new and rele-
vant factors predisposing individuals to stroke (and recov-
ery) in Brazil. Our aim is to continue patient assessment 
and blood collection, as well as begin genotyping samples 
in the near future. Some initial studies are already being 
conducted in the Laboratory of Molecular Genetics at the 
University of Campinas with the support of the Brazilian 
Institute of Neuroscience and Neurotechnology and the 
use of a genome-wide association genotyping platform 
(Affymetrix™ 6.0). 
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